Glutamatergic System Components As Potential Biomarkers and Therapeutic Targets in Cancer in Non-neural Organs

Overview

Journal Front Endocrinol (Lausanne)

Specialty Endocrinology

Date 2022 Dec 2

PMID 36457557

Authors

Ana Cristina Garcia-Gaytan

Andy Hernandez-Abrego

Mauricio Diaz-Munoz

Isabel Mendez

Affiliations

Soon will be listed here.

Abstract

Glutamate is one of the most abundant amino acids in the blood. Besides its role as a neurotransmitter in the brain, it is a key substrate in several metabolic pathways and a primary messenger that acts through its receptors outside the central nervous system (CNS). The two main types of glutamate receptors, ionotropic and metabotropic, are well characterized in CNS and have been recently analyzed for their roles in non-neural organs. Glutamate receptor expression may be particularly important for tumor growth in organs with high concentrations of glutamate and might also influence the propensity of such tumors to set metastases in glutamate-rich organs, such as the liver. The study of glutamate transporters has also acquired relevance in the physiology and pathologies outside the CNS, especially in the field of cancer research. In this review, we address the recent findings about the expression of glutamatergic system components, such as receptors and transporters, their role in the physiology and pathology of cancer in non-neural organs, and their possible use as biomarkers and therapeutic targets.

Citing Articles

A glutamatergic biomarker panel enables differentiating Grade 4 gliomas/astrocytomas from brain metastases.

Lange F, Gade R, Einsle A, Porath K, Reichart G, Maletzki C Front Oncol. 2024; 14:1335401.

PMID: 38835368 PMC: 11148222. DOI: 10.3389/fonc.2024.1335401.

Plasma Metabolite Profiling in the Search for Early-Stage Biomarkers for Lung Cancer: Some Important Breakthroughs.

Meynen J, Adriaensens P, Criel M, Louis E, Vanhove K, Thomeer M Int J Mol Sci. 2024; 25(9).

PMID: 38731909 PMC: 11083579. DOI: 10.3390/ijms25094690.

Whole-genome bisulfite sequencing identifies stage- and subtype-specific DNA methylation signatures in pancreatic cancer.

Wang S, Hall M, Lee E, Kim S, Ramesh N, Lee S iScience. 2024; 27(4):109414.

PMID: 38532888 PMC: 10963232. DOI: 10.1016/j.isci.2024.109414.

Bench-to-Bedside Studies of Arginine Deprivation in Cancer.

Field G, Pavlyk I, Szlosarek P Molecules. 2023; 28(5).

PMID: 36903394 PMC: 10005060. DOI: 10.3390/molecules28052150.

NMDA Receptor and Its Emerging Role in Cancer.

Gallo S, Vitacolonna A, Crepaldi T Int J Mol Sci. 2023; 24(3).

PMID: 36768862 PMC: 9917092. DOI: 10.3390/ijms24032540.

References

Monyer H, Seeburg P, Wisden W . Glutamate-operated channels: developmentally early and mature forms arise by alternative splicing. Neuron. 1991; 6(5):799-810. DOI: 10.1016/0896-6273(91)90176-z. View

Kang M, Cho J, Koo J, Noh S, Kim M, Kang H . The Expression of NMDA Receptor 1 Correlates with Clinicopathological Parameters in Cutaneous Squamous Cell Carcinoma. Ann Dermatol. 2010; 21(4):382-8. PMC: 2861274. DOI: 10.5021/ad.2009.21.4.382. View

Sureda F, Copani A, Bruno V, Knopfel T, Meltzger G, Nicoletti F . Metabotropic glutamate receptor agonists stimulate polyphosphoinositide hydrolysis in primary cultures of rat hepatocytes. Eur J Pharmacol. 1998; 338(2):R1-2. DOI: 10.1016/s0014-2999(97)81950-4. View

Waddell T, Miller T . Chemical evolution of the citric acid cycle: sunlight photolysis of the amino acids glutamate and aspartate. Orig Life Evol Biosph. 1991; 21(4):219-23. DOI: 10.1007/BF01809857. View

Koga T, Naraoka H . A new family of extraterrestrial amino acids in the Murchison meteorite. Sci Rep. 2017; 7(1):636. PMC: 5428853. DOI: 10.1038/s41598-017-00693-9. View

Ye Z, Wyeth M, Baltan-Tekkok S, Ransom B . Functional hemichannels in astrocytes: a novel mechanism of glutamate release. J Neurosci. 2003; 23(9):3588-96. PMC: 6742182. View

Clements J, Westbrook G . Activation kinetics reveal the number of glutamate and glycine binding sites on the N-methyl-D-aspartate receptor. Neuron. 1991; 7(4):605-13. DOI: 10.1016/0896-6273(91)90373-8. View

Wu Y, Wang N, Gu L, Yang H, Xia N, Zhang H . The suppressive effect of metabotropic glutamate receptor 5 (mGlu5) inhibition on hepatocarcinogenesis. Biochimie. 2012; 94(11):2366-75. DOI: 10.1016/j.biochi.2012.06.006. View

Miglio G, Varsaldi F, Lombardi G . Human T lymphocytes express N-methyl-D-aspartate receptors functionally active in controlling T cell activation. Biochem Biophys Res Commun. 2005; 338(4):1875-83. DOI: 10.1016/j.bbrc.2005.10.164. View

10.

Timmerman L, Holton T, Yuneva M, Louie R, Padro M, Daemen A . Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target. Cancer Cell. 2013; 24(4):450-65. PMC: 3931310. DOI: 10.1016/j.ccr.2013.08.020. View

11.

Sugano K, Maeda K, Ohtani H, Nagahara H, Shibutani M, Hirakawa K . Expression of xCT as a predictor of disease recurrence in patients with colorectal cancer. Anticancer Res. 2015; 35(2):677-82. View

12.

Wang S, Chen M, Chou Y, Ueng Y, Yin P, Yeh T . Mitochondrial dysfunction enhances cisplatin resistance in human gastric cancer cells via the ROS-activated GCN2-eIF2α-ATF4-xCT pathway. Oncotarget. 2016; 7(45):74132-74151. PMC: 5342041. DOI: 10.18632/oncotarget.12356. View

13.

Icard P, Wu Z, Fournel L, Coquerel A, Lincet H, Alifano M . ATP citrate lyase: A central metabolic enzyme in cancer. Cancer Lett. 2019; 471:125-134. DOI: 10.1016/j.canlet.2019.12.010. View

14.

Morimoto R, Uehara S, Yatsushiro S, Juge N, Hua Z, Senoh S . Secretion of L-glutamate from osteoclasts through transcytosis. EMBO J. 2006; 25(18):4175-86. PMC: 1570443. DOI: 10.1038/sj.emboj.7601317. View

15.

Gill S, Mueller R, McGuire P, Pulido O . Potential target sites in peripheral tissues for excitatory neurotransmission and excitotoxicity. Toxicol Pathol. 2000; 28(2):277-84. DOI: 10.1177/019262330002800207. View

16.

Hayashi M, Morimoto R, Yamamoto A, Moriyama Y . Expression and localization of vesicular glutamate transporters in pancreatic islets, upper gastrointestinal tract, and testis. J Histochem Cytochem. 2003; 51(10):1375-90. DOI: 10.1177/002215540305101014. View

17.

Grewer C, Gameiro A, Zhang Z, Tao Z, Braams S, Rauen T . Glutamate forward and reverse transport: from molecular mechanism to transporter-mediated release after ischemia. IUBMB Life. 2008; 60(9):609-19. PMC: 2632779. DOI: 10.1002/iub.98. View

18.

North W, Liu F, Lin L, Tian R, Akerman B . NMDA receptors are important regulators of pancreatic cancer and are potential targets for treatment. Clin Pharmacol. 2017; 9:79-86. PMC: 5522667. DOI: 10.2147/CPAA.S140057. View

19.

Shinmura K, Kato H, Igarashi H, Inoue Y, Nakamura S, Du C . CD44-SLC1A2 fusion transcripts in primary colorectal cancer. Pathol Oncol Res. 2015; 21(3):759-64. DOI: 10.1007/s12253-014-9887-2. View

20.

Zou Z, Tao T, Li H, Zhu X . mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges. Cell Biosci. 2020; 10:31. PMC: 7063815. DOI: 10.1186/s13578-020-00396-1. View